Brief: Moderna And Generation Bio Announce Strategic Collaboration To Develop Non-Viral Genetic Medicines

Generation Bio

23/03/2023 11:27

March 23 (Reuters) - Generation Bio Co  GBIO.O :
    * MODERNA AND GENERATION BIO ANNOUNCE STRATEGIC
COLLABORATION TO
DEVELOP NON-VIRAL GENETIC MEDICINES
    * GENERATION BIO CO - MODERNA WILL FUND ALL RESEARCH AND
DEVELOPMENT ACTIVITIES UNDER COLLABORATION
    * GENERATION BIO CO - MODERNA HAS ACQUIRED AN OPTION TO
LICENSE
GENERATION BIO'S CTLNP AND CLOSED-ENDED DNA (CEDNA) TECHNOLOGY
FOR TWO IMMUNE CELL PROGRAMS
    * GENERATION BIO CO - WILL RECEIVE $40 MILLION UPFRONT CASH
PAYMENT, A PRE-PAYMENT OF RESEARCH FUNDING
    * GENERATION BIO CO - MODERNA MAY ADVANCE TWO IMMUNE CELL
PROGRAMS, EACH OF WHICH MAY USE A JOINTLY DEVELOPED CTLNP TO
DELIVER CEDNA
    * GENERATION BIO CO - MODERNA HAS ACQUIRED TWO LIVER
PROGRAMS,
WITH AN ADDITIONAL OPTION FOR A THIRD IMMUNE CELL OR LIVER
PROGRAM
    * GENERATION BIO CO - MODERNA MAY ADVANCE TWO LIVER
PROGRAMS, EACH
OF WHICH MAY USE A LIVER-TARGETED CTLNP DEVELOPED BY GENERATION
BIO TO DELIVER CEDNA
    * GENERATION BIO CO - MODERNA RETAINS AN OPTION TO LICENSE A
THIRD
PROGRAM FOR EITHER IMMUNE CELLS OR LIVER
    * GENERATION BIO CO - WILL RECEIVE $36 MILLION EQUITY
INVESTMENT
FROM MODERNA, WITH POTENTIAL FOR ADDITIONAL MILESTONES, FEES,
AND ROYALTIES
    * GENERATION BIO - COS TO BOTH LEVERAGE COLLABORATION
RESEARCH TO
CONTINUE TO ADVANCE IN VIVO IMMUNE CELL TARGETING AS A NEW CLASS
OF GENETIC MEDICINES
    * GENERATION BIO CO - DEAL PROVIDES MODERNA WITH RIGHT TO
PURCHASE
ADDITIONAL SHARES OF COMMON STOCK IN CONNECTION WITH FUTURE
EQUITY FINANCING BY CO

Source text for Eikon:  ID:nGNX6v29n1 
Further company coverage:  GBIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))